MENU
+Compare
ALLO
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$1.82
Change
-$0.02 (-1.09%)
Capitalization
381.6M

ALLO Allogene Therapeutics Forecast, Technical & Fundamental Analysis

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ALLO with price predictions
Jan 08, 2025

ALLO's Stochastic Oscillator stays in overbought zone for 1 day

Expect a price pull-back in the near future.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALLO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALLO entered a downward trend on January 02, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 26, 2024. You may want to consider a long position or call options on ALLO as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALLO just turned positive on December 24, 2024. Looking at past instances where ALLO's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ALLO advanced for three days, in of 255 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ALLO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.823) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). ALLO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). ALLO's P/S Ratio (10000.000) is very high in comparison to the industry average of (264.084).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALLO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ALLO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ALLO is expected to report earnings to rise 1.41% to -32 cents per share on February 26

Allogene Therapeutics ALLO Stock Earnings Reports
Q4'24
Est.
$-0.32
Q3'24
Beat
by $0.01
Q2'24
Est.
$-0.35
Q1'24
Beat
by $0.03
Q4'23
Missed
by $0.06
The last earnings report on November 07 showed earnings per share of -31 cents, beating the estimate of -33 cents. With 2.22M shares outstanding, the current market capitalization sits at 381.60M.
A.I. Advisor
published General Information

General Information

a developer of allogeneic chimeric antigen receptor therapy

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
210 East Grand Avenue
Phone
+1 650 457-2700
Employees
233
Web
https://www.allogene.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LMCLX8.910.09
+1.02%
Miller Income I
GRMAX27.850.27
+0.98%
Nationwide S&P 500 Index A
OEGCX20.300.14
+0.69%
Invesco Discovery Mid Cap Growth C
NSFMX12.550.07
+0.56%
Natixis Target Retirement 2060 N
SSBIX12.980.07
+0.54%
State Street Balanced Index K

ALLO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with FATE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-1.09%
FATE - ALLO
59%
Loosely correlated
+1.60%
NTLA - ALLO
58%
Loosely correlated
+0.85%
CRBU - ALLO
56%
Loosely correlated
-0.65%
CRSP - ALLO
54%
Loosely correlated
+0.57%
PRME - ALLO
53%
Loosely correlated
+0.70%
More